Login to Your Account

Adagene adds $28M in series B for antibody discovery, development

By Shannon Ellis
Staff Writer

Friday, January 29, 2016

SHANGHAI – Suzhou, China-based Adagene Inc. received $28 million in series B financing to further enhance its technology-driven antibody discovery platform and nudge its own portfolio of innovative antibodies, against targets related to cancer and other diseases, closer to the clinic.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription